These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 19366906)

  • 21. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
    Suter NM; Malone KE; Daling JR; Doody DR; Ostrander EA
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):127-35. PubMed ID: 12582022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.
    Beetstra S; Suthers G; Dhillon V; Salisbury C; Turner J; Altree M; McKinnon R; Fenech M
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2565-71. PubMed ID: 18842997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
    De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Bernard L; Pensotti V; Volorio S; Ravagnani F; Radice P; Peterlongo P
    Cancer Detect Prev; 2008; 32(2):140-3. PubMed ID: 18640791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population.
    Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Ohtake N; Takei T; Nakata S; Hasumi M; Yamanaka H
    Anticancer Res; 2003; 23(6D):4941-6. PubMed ID: 14981949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women.
    Kataoka N; Cai Q; Wen W; Shu XO; Jin F; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1148-52. PubMed ID: 16775174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
    Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
    Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
    Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
    J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
    Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
    Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease family history and modification of breast cancer risk in common BRCA2 variants.
    Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Falcini F; Strada M; Morini N; Naldoni C; Paradiso A; Tommasi S; Schittulli F; Amadori D; Calistri D
    Oncol Rep; 2008 Mar; 19(3):783-6. PubMed ID: 18288416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A role for XRCC4 in age at diagnosis and breast cancer risk.
    Allen-Brady K; Cannon-Albright LA; Neuhausen SL; Camp NJ
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1306-10. PubMed ID: 16835328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variants of CYP19 (aromatase) and breast cancer risk.
    Kristensen VN; Harada N; Yoshimura N; Haraldsen E; Lonning PE; Erikstein B; Kåresen R; Kristensen T; Børresen-Dale AL
    Oncogene; 2000 Mar; 19(10):1329-33. PubMed ID: 10713674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
    Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
    Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
    Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene.
    Cui Y; Shu XO; Cai Q; Jin F; Cheng JR; Cai H; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1096-101. PubMed ID: 15894658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study.
    Soucek P; Borovanova T; Pohlreich P; Kleibl Z; Novotny J
    Breast Cancer Res Treat; 2007 Jun; 103(2):219-24. PubMed ID: 17039264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.
    Osorio A; Martínez-Delgado B; Pollán M; Cuadros M; Urioste M; Torrenteras C; Melchor L; Díez O; De La Hoya M; Velasco E; González-Sarmiento R; Caldés T; Alonso C; Benítez J
    Hum Mutat; 2006 Mar; 27(3):242-8. PubMed ID: 16419081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
    Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
    Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
    Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN
    Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
    Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
    Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.